Using CDK4/6 inhibitor and less chemo for early HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a stronger treatment (a CDK4/6 inhibitor) combined with less chemotherapy for early-stage breast cancer that is positive for hormone receptors and HER2. It aims to see if this approach works well while reducing side effects from chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have early-stage breast cancer (stage I) that has not spread to lymph nodes and is smaller than 2 cm.
- Your cancer is estrogen-receptor positive (at least 50% of cells have receptors).
- Your cancer is HER2-positive (either strong overexpression or a weak result with gene amplification confirmed by a special test).
- Your cancer is low or medium grade, or if it is high grade, it is small (≤1 cm) or shows a luminal pattern on molecular testing.
- Your heart, blood, liver, and kidney function are within normal limits, and you are not pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three anti-HER2 drugs plus a CDK4/6 inhibitor before surgery for women with a type of breast cancer that is both HER2-positive and ER-positive. It aims to see if this treatment can shrink tumors more effectively before surgery.
This trial tests whether it is safe to skip chemotherapy after surgery for certain patients with early-stage, hormone-receptor positive, HER2-negative breast cancer that has not spread to lymph nodes. Instead, they would receive hormone therapy plus a targeted CDK4/6 inhibitor (a pill that blocks cancer cell growth).
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This trial tests a chemotherapy-free approach for women age 65 and older with a common type of breast cancer (ER-positive, HER2-negative) that has spread to lymph nodes. Instead of chemotherapy, you would receive an oral targeted therapy (CDK4/6 inhibitor) after surgery to see if it can prevent the cancer from coming back.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial tests giving a CDK4/6 inhibitor (a drug that blocks cancer cell growth) at the same time as radiation after surgery. It is for women with a specific type of breast cancer (hormone receptor-positive, HER2-negative) that has a high risk of coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.